Posted by Michael Wonder on 06 Jan 2026
Oculis announces US FDA breakthrough therapy designation granted to privosegtor for treatment of optic neuritis
6 January 2026 - Oculis today announced that its neuroprotective candidate privosegtor was granted breakthrough therapy designation by the US FDA for treatment of optic neuritis.
The FDA’s breakthrough therapy designation for privosegtor is supported by visual function results from the Phase 2 ACUITY trial in optic neuritis, a rare, sight‑threatening neuro‑ophthalmic condition that is often the first clinical manifestation of multiple sclerosis.
